What role does drug development investment play in lurbinectedin's cost?

Drug development investment plays a big role in the overall cost of lurbinectedin because those R&D expenses have to be recovered (at least partly) by the drug’s later pricing and by covering the financial risk taken during development.

Key ways that investment affects cost:

• Recouping R&D spending: Lurbinectedin’s developer-funded costs include discovery, preclinical work, multiple phases of clinical trials (Phase 1/2/3), manufacturing scale-up, and regulatory work. Those investments are typically millions to billions of dollars across a whole portfolio of drug candidates, and successful products must help recoup that spend.

• Clinical-trial “risk premium”: Not every candidate succeeds. Because many compounds fail, the investments in failed programs indirectly increase the amount a successful drug may need to generate to justify the overall R&D strategy.

• Ongoing development and lifecycle costs: Even after initial approval, companies often continue studies (new indications, dosing optimization, combinations, long-term safety). Those additional investments can influence pricing.

• Manufacturing scale-up and compliance: Developing a drug is not only clinical—there are also quality, regulatory, and process-development costs (e.g., ensuring consistent manufacturing, stability testing, and cGMP production). Early manufacturing may be expensive until supply chains mature.

• Time value of money: Money invested years earlier has a “cost of capital” component. Pricing often reflects the fact that returns are needed after a long development timeline.

If you tell me which country/price you’re looking at (e.g., US list price, hospital acquisition cost, UK NHS, etc.) I can also explain how development investment interacts with other factors like exclusivity, payer negotiations, generic/biosimilar competition (if any), and distribution margins.